Plasma proprotein convertase subtilisin/kexin type 9: A marker of LDL apolipoprotein B-100 catabolism?

Clinical Chemistry

Volumn 55, Issue 11, 2009, Pages 2049-2052

  Chan, Dick C ^a   Lambert, Gilles ^b,c   Barrett, P Hugh R ^a   Rye, Kerry Anne ^b,d   Ooi, Esther M M ^a   Watts, Gerald F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b HEART RESEARCH INSTITUTE   (Australia)

^c UNIVERSITÉ DE NANTES   (France)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL; KEXIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPORTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; INSULIN; LATHOSTEROL; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ARTICLE; CATABOLISM; HUMAN; MASS FRAGMENTOGRAPHY; PROTEIN BLOOD LEVEL; ADULT; AGED; BLOOD; BODY MASS; MALE; METABOLISM; MIDDLE AGED;

ADULT; AGED; APOLIPOPROTEIN B-100; BIOLOGICAL MARKERS; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, LDL; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INSULIN; MALE; MIDDLE AGED; SERINE ENDOPEPTIDASES;

EID: 70449732531     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.128645     Document Type: Article

References (20)

1. Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, Warnick GR. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009;55:407-419
2. Segrest JP, Jones MK, De Loof H, Dashti N. Structure of apolipoprotein B-100 in low density lipoproteins. J Lipid Res 2001;42:1346-1367 (Pubitemid 34007665)
3. Marsh JB, Welty FK, Lichtenstein AH, Lamon-Fava S, Schaefer EJ. Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis 2002;162: 227-244 (Pubitemid 34457929)
4. Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003;52:803-811 (Pubitemid 36323589)
5. Chan DC, Watts GF, Redgrave TG, Mori TA, Barrett PH. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism 2002;51:1041-1046 (Pubitemid 34884307)
6. Lambert G, Charlton F, Rye KA, Piper DE. Molecular basis of PCSK9 function. Atherosclerosis 2009;203:1-7.
7. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-156 (Pubitemid 36666925)
8. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-1272
9. Grefhorst A, McNutt MC, Lagace TA, Horton JD. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res 2008;49:1303-1311
10. Lambert G, Ancellin N, Charlton F, Comas D, Pilot J, Keech A, et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008;54:1038-1045 (Pubitemid 351793411)
11. Mayne J, Raymond A, Chaplin A, Cousins M, Kaefer N, Gyamera A, et al. Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem Biophys Res Commun 2007; 361:451-456 (Pubitemid 47193117)
12. Alborn WE, Cao G, Careskey HE, Qian YW, Subramaniam DR, Davies J, et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 2007;53:1814-1819 (Pubitemid 47509675)
13. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008;49:394-398 (Pubitemid 351213624)
14. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106: 3143-3421
15. Ouguerram K, Chetiveaux M, Zair Y, Costet P, Abifadel M, Varret M, et al. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol 2004;24:1448-1453 (Pubitemid 39050439)
16. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009;29:431-438
17. Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res 2008;49:399-409. (Pubitemid 351213625)
18. Brown MS, Goldstein JL. Regulation of the activity of the low density lipoprotein receptor in human fibroblasts. Cell 1975;6:307-316
19. Brodsky JL, Fisher EA. The many intersecting pathways underlying apolipoprotein B secretion and degradation. Trends Endocrinol Metab 2008; 19:254-259
20. Cao G, Qian YW, Kowala MC, Konrad RJ. Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease. Endocr Metab Immune Disord Drug Targets 2008;8:238-243